Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen

Journal of Immunology

Volumn 185, Issue 8, 2010, Pages 4590-4601

  Sabarth, Nicolas ^a,b   Chamberlain, Louise ^a   Brett, Sara ^a   Tite, John ^a,c   Craigen, Jenny ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Baxter Innovations ^*  (Austria)

^c Babraham Research Campus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMIQUIMOD; TOLL LIKE RECEPTOR 7; CANCER VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; DNA IMMUNIZATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; MOUSE; NEOPLASM; NONHUMAN; PLASMID; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL SEPARATION; CHICKEN; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CHICKENS; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; RATS;

EID: 78049490550     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803994     Document Type: Article

References (59)

1. Stevenson, F. K., C. H. Ottensmeier, P. Johnson, D. Zhu, S. L. Buchan, K. J. McCann, J. S. Roddick, A. T. King, F. McNicholl, N. Savelyeva, and J. Rice. 2004. DNA vaccines to attack cancer. Proc. Natl. Acad. Sci. USA 101 (Suppl 2):14646-14652.
2. Perales, M. A., G. Fantuzzi, S. M. Goldberg, M. J. Turk, F. Mortazavi, K. Busam, A. N. Houghton, C. A. Dinarello, and J. D. Wolchok. 2002. GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell. Mol. Ther. 7:125-133.
3. Haddad, D., J. Ramprakash, M. Sedegah, Y. Charoenvit, R. Baumgartner, S. Kumar, S. L. Hoffman, and W. R. Weiss. 2000. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. 165:3772-3781.
4. Bowne, W. B., J. D. Wolchok, W. G. Hawkins, R. Srinivasan, P. Gregor, N. E. Blachere, Y. Moroi, M. E. Engelhorn, A. N. Houghton, and J. J. Lewis. 1999. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell. Mol. Ther. 5:217-225.
5. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
6. Matthews, K., S. M. Rhind, A. G. Gossner, R. G. Dalziel, and J. Hopkins. 2007. The effect of gene gun-delivered pGM-CSF on the immunopathology of the vaccinated skin. Scand. J. Immunol. 65:298-307.
7. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200.
8. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3:499.
9. Harrison, C. J., R. L. Miller, and D. I. Bernstein. 1994. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. 38:2059-2064.
10. Thomsen, L. L., P. Topley, M. G. Daly, S. J. Brett, and J. P. Tite. 2004. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799-1809.
11. Rechtsteiner, G., T. Warger, P. Osterloh, H. Schild, and M. P. Radsak. 2005. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174:2476-2480.
12. Burns, R. P., Jr., B. Ferbel, M. Tomai, R. Miller, and A. A. Gaspari. 2000. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin. Immunol. 94:13-23.
13. Janssen, E. M., E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath, and S. P. Schoenberger. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-856.
14. Sun, J. C., M. A. Williams, and M. J. Bevan. 2004. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5:927-933.
15. Antony, P. A., C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174:2591-2601.
16. Bennett, S. R., F. R. Carbone, F. Karamalis, J. F. Miller, and W. R. Heath. 1997. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186:65-70.
17. King, C. A., M. B. Spellerberg, D. Zhu, J. Rice, S. S. Sahota, A. R. Thompsett, T. J. Hamblin, J. Radl, and F. K. Stevenson. 1998. DNA vaccines with singlechain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4:1281-1286.
18. La Rosa, C., Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, and D. J. Diamond. 2002. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100:3681-3689.
19. Mukherjee, P., L. B. Pathangey, J. B. Bradley, T. L. Tinder, G. D. Basu, E. T. Akporiaye, and S. J. Gendler. 2007. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 25:1607-1618.
20. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Sette, et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751-761.
21. Kurts, C. 2000. Cross-presentation: inducing CD8 T cell immunity and tolerance. J. Mol. Med. 78:326-332.
22. Kurts, C., R. M. Sutherland, G. Davey, M. Li, A. M. Lew, E. Blanas, F. R. Carbone, J. F. Miller, and W. R. Heath. 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96:12703-12707.
23. Eisenbraun, M. D., D. H. Fuller, and J. R. Haynes. 1993. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12:791-797.
24. Steinaa, L., P. B. Rasmussen, J. Rygaard, S. Mouritsen, and A. Gautam. 2007. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes. Scand. J. Immunol. 65:240-248.
25. Kohyama, M., D. Sugahara, S. Sugiyama, H. Yagita, K. Okumura, and N. Hozumi. 2004. Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc. Natl. Acad. Sci. USA 101:4192-4197.
26. Dredge, K., J. B. Marriott, S. M. Todryk, and A. G. Dalgleish. 2002. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother. 51:521-531.
27. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
28. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:617-627.
29. Marzo, A. L., B. F. Kinnear, R. A. Lake, J. J. Frelinger, E. J. Collins, B. W. Robinson, and B. Scott. 2000. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165:6047-6055.
30. Sugauchi, F., R. Y. Wang, Q. Qiu, B. Jin, H. J. Alter, and J. W. Shih. 2006. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. J. Infect. Dis. 193:563-572.
31. Liu, H. M., S. E. Newbrough, S. K. Bhatia, C. E. Dahle, A. M. Krieg, and G. J. Weiner. 1998. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 92:3730-3736.
32. Edwards, A. D., S. S. Diebold, E. M. Slack, H. Tomizawa, H. Hemmi, T. Kaisho, S. Akira, and C. Reis e Sousa. 2003. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33:827-833.
33. Ito, T., R. Amakawa, T. Kaisho, H. Hemmi, K. Tajima, K. Uehira, Y. Ozaki, H. Tomizawa, S. Akira, and S. Fukuhara. 2002. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195:1507-1512.
34. Randolph, G. J., J. Ochando, and S. Partida-Sánchez. 2008. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26:293-316.
35. Doxsee, C. L., T. R. Riter, M. J. Reiter, S. J. Gibson, J. P. Vasilakos, and R. M. Kedl. 2003. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b +CD8-dendritic cells. J. Immunol. 171:1156-1163.
36. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339-342.
37. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339.
38. Cibotti, R., J. M. Kanellopoulos, J. P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Kourilsky. 1992. Tolerance to a selfprotein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89:416-420.
39. Targoni, O. S., and P. V. Lehmann. 1998. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J. Exp. Med. 187:2055-2063.
40. Del Guercio, M. F., J. Alexander, R. T. Kubo, T. Arrhenius, A. Maewal, E. Appella, S. L. Hoffman, T. Jones, D. Valmori, K. Sakaguchi, et al. 1997. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15:441-448.
41. Livingston, B. D., J. Alexander, C. Crimi, C. Oseroff, E. Celis, K. Daly, L. G. Guidotti, F. V. Chisari, J. Fikes, R. W. Chesnut, and A. Sette. 1999. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 162:3088-3095.
42. Rosa, D. S., F. Tzelepis, M. G. Cunha, I. S. Soares, and M. M. Rodrigues. 2004. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol. Lett. 92:259-268.
43. Wei, W. Z., S. Ratner, T. Shibuya, G. Yoo, and A. Jani. 2001. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. J. Immunol. Methods 258:141-150.
44. Daftarian, P., M. Mansour, A. C. Benoit, B. Pohajdak, D. W. Hoskin, R. G. Brown, and W. M. Kast. 2006. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24:5235-5244.
45. Decroix, N., P. Pamonsinlapatham, C. P. Quan, and J. P. Bouvet. 2003. Impairment by mucosal adjuvants and cross-reactivity with variant peptides of the mucosal immunity induced by injection of the fusion peptide PADRE-ELD-KWA. Clin. Diagn. Lab. Immunol. 10:1103-1108.
46. Tan, T. T., and L. M. Coussens. 2007. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 19:209-216.
47. Sant, A. J., F. A. Chaves, S. A. Jenks, K. A. Richards, P. Menges, J. M. Weaver, and C. A. Lazarski. 2005. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II: peptide complexes. Immunol. Rev. 207:261-278.
48. Kariyone, A., T. Tamura, H. Kano, Y. Iwakura, K. Takeda, S. Akira, and K. Takatsu. 2003. Immunogenicity of Peptide-25 of Ag85B in Th1 development: role of IFN-gamma. Int. Immunol. 15:1183-1194.
49. Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete for access to antigen-bearing antigenpresenting cells. J. Exp. Med. 192:1105-1113.
50. La Gruta, N. L., K. Kedzierska, K. Pang, R. Webby, M. Davenport, W. Chen, S. J. Turner, and P. C. Doherty. 2006. A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc. Natl. Acad. Sci. USA 103:994-999.
51. Jenkins, M. R., R. Webby, P. C. Doherty, and S. J. Turner. 2006. Addition of a prominent epitope affects influenza A virus-specific CD8+ T cell immunodominance hierarchies when antigen is limiting. J. Immunol. 177:2917-2925.
52. Garcia, Z., E. Pradelli, S. Celli, H. Beuneu, A. Simon, and P. Bousso. 2007. Competition for antigen determines the stability of T cell-dendritic cell interactions during clonal expansion. Proc. Natl. Acad. Sci. USA 104:4553-4558.
53. Blair, D. A., and L. Lefrançois. 2007. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc. Natl. Acad. Sci. USA 104:15045-15050.
54. Behrens, G., M. Li, C. M. Smith, G. T. Belz, J. Mintern, F. R. Carbone, and W. R. Heath. 2004. Helper T cells, dendritic cells and CTL Immunity. Immunol. Cell Biol. 82:84-90.
55. Beuneu, H., Z. Garcia, and P. Bousso. 2006. Cutting edge: cognate CD4 help promotes recruitment of antigen-specific CD8 T cells around dendritic cells. J. Immunol. 177:1406-1410.
56. Cose, S., C. Brammer, D. J. Zammit, D. A. Blair, and L. Lefrançois. 2006. CD4 T cells inhibit the CD8 T cell response during low-dose virus infection. Int. Immunol. 18:1285-1293.
57. Ludewig, B., A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191:795-804.
58. Craft, N., K. W. Bruhn, B. D. Nguyen, R. Prins, J. W. Lin, L. M. Liau, and J. F. Miller. 2005. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol. 175:1983-1990.
59. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced bycytotoxicTlymphocyte- associated antigen4blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100:8372-8377.